Lake Street lowered the firm’s price target on Avita Medical (RCEL) to $3 from $4 and keeps a Hold rating on the shares. The firm remains on the sidelines until seeing sales stabilization and reacceleration and a more permanent financial solution to the balance sheet, the analyst tells investors in a post-earnings note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL: